Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy
For many types of cancer, immune checkpoint inhibitors have proven to be a highly effective treatment. The monoclonal anti-PD-1 antibody nivolumab stimulates the immune system and is one of the newest treatment options for non-small cell lung cancer. In doing so, immune checkpoint inhibitors can tri...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2019.00262/full |
| _version_ | 1818962131428573184 |
|---|---|
| author | Sebastian Krammer Christian Krammer Suzanna Salzer Işin Sinem Bağci Lars E. French Lars E. French Daniela Hartmann Daniela Hartmann |
| author_facet | Sebastian Krammer Christian Krammer Suzanna Salzer Işin Sinem Bağci Lars E. French Lars E. French Daniela Hartmann Daniela Hartmann |
| author_sort | Sebastian Krammer |
| collection | DOAJ |
| description | For many types of cancer, immune checkpoint inhibitors have proven to be a highly effective treatment. The monoclonal anti-PD-1 antibody nivolumab stimulates the immune system and is one of the newest treatment options for non-small cell lung cancer. In doing so, immune checkpoint inhibitors can trigger many skin lesions that have not yet been completely investigated in their entirety. In this case report, pemphigus vulgaris is identified as a potential adverse event that occurs under the treatment with nivolumab. In addition to the standard methods, we examined our patient's samples with ex vivo confocal laser scanning microscopy. This is a new and innovative diagnostic method that uses vertical scanning to provide fast, high-resolution imaging of freshly excised tissue, even using fluorescently labeled antibodies. |
| first_indexed | 2024-12-20T12:24:27Z |
| format | Article |
| id | doaj.art-d1f181430b77412b9623fdd80a434520 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-20T12:24:27Z |
| publishDate | 2019-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-d1f181430b77412b9623fdd80a4345202022-12-21T19:40:53ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2019-11-01610.3389/fmed.2019.00262498811Recurrence of Pemphigus Vulgaris Under Nivolumab TherapySebastian Krammer0Christian Krammer1Suzanna Salzer2Işin Sinem Bağci3Lars E. French4Lars E. French5Daniela Hartmann6Daniela Hartmann7Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, GermanyDepartment of Dermatology and Allergology, University Hospital, LMU Munich, Munich, GermanyDepartment of Dermatology, Municipal Hospital of Munich, Munich, GermanyDepartment of Dermatology and Allergology, University Hospital, LMU Munich, Munich, GermanyDepartment of Dermatology and Allergology, University Hospital, LMU Munich, Munich, GermanyDepartment of Dermatology, Municipal Hospital of Munich, Munich, GermanyDepartment of Dermatology and Allergology, University Hospital, LMU Munich, Munich, GermanyDepartment of Dermatology, Municipal Hospital of Munich, Munich, GermanyFor many types of cancer, immune checkpoint inhibitors have proven to be a highly effective treatment. The monoclonal anti-PD-1 antibody nivolumab stimulates the immune system and is one of the newest treatment options for non-small cell lung cancer. In doing so, immune checkpoint inhibitors can trigger many skin lesions that have not yet been completely investigated in their entirety. In this case report, pemphigus vulgaris is identified as a potential adverse event that occurs under the treatment with nivolumab. In addition to the standard methods, we examined our patient's samples with ex vivo confocal laser scanning microscopy. This is a new and innovative diagnostic method that uses vertical scanning to provide fast, high-resolution imaging of freshly excised tissue, even using fluorescently labeled antibodies.https://www.frontiersin.org/article/10.3389/fmed.2019.00262/fullpemphigus vulgarisnivolumabPD-1checkpoint inhibitorsautoimmune diseaseautoimmune vesiculobullous disease |
| spellingShingle | Sebastian Krammer Christian Krammer Suzanna Salzer Işin Sinem Bağci Lars E. French Lars E. French Daniela Hartmann Daniela Hartmann Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy Frontiers in Medicine pemphigus vulgaris nivolumab PD-1 checkpoint inhibitors autoimmune disease autoimmune vesiculobullous disease |
| title | Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy |
| title_full | Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy |
| title_fullStr | Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy |
| title_full_unstemmed | Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy |
| title_short | Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy |
| title_sort | recurrence of pemphigus vulgaris under nivolumab therapy |
| topic | pemphigus vulgaris nivolumab PD-1 checkpoint inhibitors autoimmune disease autoimmune vesiculobullous disease |
| url | https://www.frontiersin.org/article/10.3389/fmed.2019.00262/full |
| work_keys_str_mv | AT sebastiankrammer recurrenceofpemphigusvulgarisundernivolumabtherapy AT christiankrammer recurrenceofpemphigusvulgarisundernivolumabtherapy AT suzannasalzer recurrenceofpemphigusvulgarisundernivolumabtherapy AT isinsinembagci recurrenceofpemphigusvulgarisundernivolumabtherapy AT larsefrench recurrenceofpemphigusvulgarisundernivolumabtherapy AT larsefrench recurrenceofpemphigusvulgarisundernivolumabtherapy AT danielahartmann recurrenceofpemphigusvulgarisundernivolumabtherapy AT danielahartmann recurrenceofpemphigusvulgarisundernivolumabtherapy |